Therefore, we propose that, in view of their poor overall survival cancer patients who have decreased expression level of MLKL in tumor tissues may potentially receive a clinical benefit from TRAIL receptor agonist therapy, as these patients’ cancers may be more potentially responsive to TRAIL therapy. The gene discussed is TNFSF10; the disease is neoplasm.